

## 2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against *E. coli*, *S. aureus*, HSV-1, and RSV

François Chouinard,<sup>\*,†</sup> Caroline Turcotte,<sup>\*,†</sup> Xiaochun Guan,<sup>‡</sup> Marie-Chantal Larose,<sup>\*,†</sup>  
Samuel Poirier,<sup>\*,†</sup> Line Bouchard,<sup>\*,†</sup> Véronique Provost,<sup>\*,†</sup> Louis Flamand,<sup>†,§</sup>  
Nathalie Grandvaux,<sup>‡</sup> and Nicolas Flamand<sup>\*,†,1</sup>

\*Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Département de Médecine, Québec City, Canada; †Centre de Recherche du CHUM, Département de Biochimie, Faculté de Médecine, Université de Montréal, Montréal, Canada; ‡Centre de Recherche du CHUQ, Département de Microbiologie, Infectiologie et Immunologie, and †Faculté de Médecine, Université Laval, Québec City, Canada

RECEIVED APRIL 20, 2012; REVISED NOVEMBER 13, 2012; ACCEPTED NOVEMBER 27, 2012. DOI: 10.1189/jlb.0412200

### ABSTRACT

The endocannabinoid 2-AG is highly susceptible to its hydrolysis into AA, which activates neutrophils through de novo LTB<sub>4</sub> biosynthesis, independently of CB activation. In this study, we show that 2-AG and AA stimulate neutrophils to release antimicrobial effectors. Supernatants of neutrophils activated with nanomolar concentrations of 2-AG and AA indeed inhibited the infectivity of HSV-1 and RSV. Additionally, the supernatants of 2-AG- and AA-stimulated neutrophils strongly impaired the growth of *Escherichia coli* and *Staphylococcus aureus*. This correlated with the release of a large amount (micrograms) of  $\alpha$ -defensins, as well as a limited amount (nanograms) of LL-37. All the effects of AA and 2-AG mentioned above were prevented by inhibiting LTB<sub>4</sub> biosynthesis or by blocking BLT<sub>1</sub>. Importantly, neither CB<sub>2</sub> receptor agonists nor antagonists could mimic nor prevent the effects of 2-AG, respectively. In fact, qPCR data show that contaminating eosinophils express ~100-fold more CB<sub>2</sub> receptor mRNA than purified neutrophils, suggesting that CB<sub>2</sub> receptor expression by human neutrophils is limited and that contaminating eosinophils are likely responsible for the previously documented CB<sub>2</sub> expression by freshly isolated human

neutrophils. The rapid conversion of 2-AG to AA and their subsequent metabolism into LTB<sub>4</sub> promote 2-AG and AA as multifunctional activators of neutrophils, mainly exerting their effects by activating the BLT<sub>1</sub>. Considering that nanomolar concentrations of AA or 2-AG were sufficient to impair viral infectivity, this suggests potential physiological roles for 2-AG and AA as regulators of host defense in vivo. *J. Leukoc. Biol.* **93**: 267–276; 2013.

### Introduction

Neutrophils play an important role in host defense by participating in pathogen clearance. They fulfil this important function notably by releasing antimicrobial peptides, by producing ROS, and by ingesting and killing microbes. Neutrophils represent a rich source of antimicrobial peptides, such as  $\alpha$ -defensins and the cathelicidin LL-37.  $\alpha$ -Defensins are small, cationic peptides accounting for ~5% of neutrophil proteins, and LL-37 is an  $\alpha$ -helix peptide containing 37 aa that originates from the C-terminal domain of the cathelicidin human cationic antimicrobial protein-18. In addition to their antimicrobial properties against viruses and bacteria [1–4],  $\alpha$ -defensins and LL-37 recruit and activate leukocytes [5–13].

One of the main bioactive ingredients of cannabis, THC was previously shown to increase the susceptibility of mice to bacterial, protozoan, and viral infections [14–17]. This effect of THC is linked to CB<sub>2</sub> receptor activation, decreased phagocytosis by macrophages, down-regulation of proinflammatory cytokine production, and the polarization of T cells toward a Th2 phenotype [18–23]. Although CB<sub>2</sub> receptor activation is usually considered anti-inflammatory, endocannabinoids, such

Abbreviations: 2-AG=2-arachidonoyl-glycerol, AA=arachidonic acid, ADA=adenosine deaminase, AEA=N-arachidonyl ethanolamine, AM-251=N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole 3-carboxamide, BLT<sub>1</sub>=leukotriene B<sub>4</sub> receptor 1, CB=cannabinoid receptor, CIHR=Canadian Institutes of Health Research, DPI=diphenylethylideneiodonium, FLAP=5-lipoxygenase-activating protein, GPR55=GPCR 55, HSV-1=herpes simplex virus 1, LT=leukotriene, MAFP=methyl-arachidonyl-fluorophosphonate, O-2050=(6aR,10aR)-3-(1-methanesulfonyl-amino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzopyran, O<sub>2</sub><sup>-</sup>=superoxide anion, qPCR=quantitative PCR, RSV=respiratory syncytial virus, SR144528=5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide, THC=(-)- $\Delta^9$ -tetrahydrocannabinol, TSB=tryptic soy broth

1. Correspondence: Centre de Recherche de l'UICPQ, 2725 Chemin Sainte-Foy, Office M2662, Québec City, QC G1V 4G5, Canada. E-mail: nicolas.flamand@criucpq.ulaval.ca

as AEA and 2-AG, can enhance cell functions, such as chemotaxis, phagocytosis, and the release of soluble mediators [21, 24–33].

The pro- and anti-inflammatory effects of endocannabinoids are likely explained by a differential expression of CB receptors among leukocytes and the activation of additional cell surface receptors by endocannabinoid metabolites. 2-AG and AEA are indeed the respective precursors of other bioactive lipids, such as PGs-glycerol and prostamides [34, 35], as well as being a significant source of AA, leading to the biosynthesis of eicosanoids [36, 37]. We indeed documented that 2-AG was rapidly hydrolyzed to AA and further converted into LTB<sub>4</sub> by human neutrophils [36]. Given that LTB<sub>4</sub> promotes the ingestion and killing of microbes and the release of antimicrobial peptides [38–42], we postulated that 2-AG and AA would have similar effects. In this study, we investigated the antimicrobial activities of human neutrophils activated by 2-AG or AA.

## MATERIALS AND METHODS

### Material

2-AG ether, 2-AG, AA, AEA, SR144528, LTB<sub>4</sub>, and MAFP were purchased from Cayman Chemical (Ann Arbor, MI, USA). O-2050, AM-251, and DPI were obtained from Tocris Bioscience (Ellisville, MO, USA). ADA was purchased from Roche Applied Science (Indianapolis, IN, USA). fMLP, cytochalasin B, DMSO, dextran, and methyl cellulose were obtained from Sigma Chemical Co. (St. Louis, MO, USA). HBSS, lymphocyte separation medium, M199, FBS, penicillin, streptomycin, and amphotericin B were obtained from Wisent Laboratories (St-Bruno, Quebec, Canada). The magnetic bead-conjugated anti-CD16 mAb and MACS were purchased from Miltenyi Biotec (Auburn, CA, USA). Purified human LL-37 and  $\alpha$ -defensins, which consist of a 5:4:1 mixture of  $\alpha$ -defensin-1, -2, and -3, as well as LL-37 and  $\alpha$ -defensin ELISA kits were obtained from Hycult Biotechnologies (Uden, The Netherlands). The FLAP antagonist MK-0591 was provided by Dr. Denis Riendeau from Merck Frosst (Kirkland, Quebec, Canada). *E. coli* (clinical isolate; ATCC #25922), *S. aureus* (clinical isolate; ATCC #25923), Vero cells (ATCC #CCL-81), and HSV-1 (MacIntyre strain; ATCC #VR-539) were obtained from the American Type Culture Collection (Manassas, VA, USA). rRSV encoding GFP was kindly provided by Dr. Peter Collins (U.S. National Institutes of Health, Bethesda, MD, USA). Shaphylokinase and aureolysin were, respectively, obtained from Cedarlane (Burlington, Ontario, Canada) and Axxora (Farmingdale, NY, USA).

### Ethics Committee approval

This work required the use of human cells from healthy volunteers and was approved by the Institutional Ethics Committee from the Institut Universitaire de Cardiologie et de Pneumologie de Québec. All of the experiments were conducted with the understanding and the signed consent of each participant.

### Isolation of human neutrophils

Venous blood was obtained from healthy volunteers in K<sub>3</sub> EDTA tubes, and neutrophils were purified, as described before with slight modifications [43]. In brief, blood was centrifuged (17 min; 250 g) to remove the platelet-rich plasma. Erythrocytes then were sedimented with 3% dextran. PBMCs were discarded from the granulocytes by centrifugation on a discontinuous gradient by using lymphocyte separation medium cushions. A hypotonic lysis with sterile water was next performed on the granulocyte pellet to eliminate the residual erythrocytes. Neutrophils were finally purified from the granulocyte suspension by positive selection with anti-CD16-conjugated magnetic beads, according to the manufacturer's instructions.

The purity and viability of the resulting neutrophil and eosinophil suspensions were always  $\geq 98.5\%$ , as assessed by Diff-Quick staining and trypan blue exclusion, respectively.

### Analysis of $\alpha$ -defensins and LL-37

Supernatant of human neutrophils was analyzed for  $\alpha$ -defensins and LL-37 content by ELISA (Hycult Biotechnologies), according to the manufacturer's instructions.

### Analysis of CB<sub>2</sub> expression by RT-PCR and qPCR

Total RNA of granulocytes, neutrophils, and eosinophils was extracted with TRIzol, according to the manufacturer's instructions. For the analysis of CB<sub>2</sub> expression by RT-PCR, experiments were performed in a single tube using Qiagen OneStep RT-PCR kit. In brief, 50 ng total RNA was reverse-transcribed for 30 min and then amplified on a Peltier Thermal Cycler (PTC-200; MJ Research, Watertown, MA, USA) during 28 cycles with the following parameters: denaturation at 94°C for 1 min (2 min for the first cycle), annealing at 60°C for 30 s, and extension at 72°C for 1 min (5 min for the last cycle). After cycling, the amplicons were resolved by electrophoresis on ethidium bromide-stained 2% agarose gels, and the fluorescent bands were visualized using a UV transilluminator. The Chemgenius software (Syngene, Frederick, MD, USA) was then used to capture the images. Primer sequences were CB<sub>2</sub> (CNR2; NM\_001841.2) forward, 5'-CCACAA-CACAACCCAAAGC-3'; CB<sub>2</sub> reverse, 5'-GCAGAGGTATCGGTCAATGG-3'. For qPCR analyses, total RNA was extracted using TRIzol, followed by a treatment with the RNase-free DNase set (Qiagen, Valencia, CA, USA) to eliminate residual genomic DNA. Samples were cleaned and concentrated with the RNeasy MinElute cleanup kit (Qiagen) and then quantified spectrophotometrically at 260 nm using a Synergy H1 microplate reader and the Take3 trio plate (BioTek, Winooski, VT, USA). cDNAs were obtained using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). qPCR reactions were performed with the iQ SYBR Green Supermix (Bio-Rad) on a CFX96 Bio-Rad thermal cycler instrument. cDNA samples, obtained from 8 ng total RNA, were used in a reaction volume of 25  $\mu$ l with specific primers for human CB<sub>2</sub> (NM\_001841) and human 18S rRNA (X03205) from Qiagen.

### Dialysis of ADA and removal of endogenous adenosine

ADA was dialyzed using a Slide-A-Lyzer dialysis device (3.5 kDa MW cutoff; Thermo Fisher Scientific, Waltham, MA, USA). Sterile dialysis was performed in a beaker containing 0.9% NaCl and 10 mM Hepes (pH 7.4) with constant stirring. The buffered saline solution was changed after 1.5 and 3 h, and then the content was dialyzed overnight at 4°C. ADA was harvested from the dialysis device and then assessed for its ability to hydrolyze adenosine. To prevent the extracellular buildup of adenosine observed in isolated neutrophil suspensions, which results in the inhibition of neutrophil functions, ADA (0.3 U/ml) was always added to samples 10 min prior to stimulation [44].

### Stimulation of human neutrophils

Prewarmed human neutrophil suspensions (37°C;  $2 \times 10^7$  cells/ml) in HBSS, containing 1.6 mM CaCl<sub>2</sub>, were treated with 1  $\mu$ M cytochalasin B for 15 min and then activated with LTB<sub>4</sub>, fMLP, 2-AG, AA, AEA, or 2-AG ether for the indicated times and concentrations (see figure legends). Incubations were stopped by placing the samples in an ice-water bath for 5 min. Samples then were centrifuged (4°C; 5 min; 700 g), and the cell-free supernatants were collected and frozen until further analyses. Addition of enzyme inhibitors or receptor antagonists was performed 5 min before the addition of the stimuli.

### O<sub>2</sub><sup>-</sup> release

The release of O<sub>2</sub><sup>-</sup> by human neutrophils was assessed by cytochrome *c* reduction, as described previously with minor modifications [45]. In brief,

prewarmed human neutrophil suspensions ( $37^{\circ}\text{C}$ ;  $2 \times 10^7$  cells/ml) in HBSS, containing 1.6 mM  $\text{CaCl}_2$ , were treated with  $10 \mu\text{M}$  cytochalasin B for 15 min and then activated with 2-AG ( $3 \mu\text{M}$ ), AA ( $3 \mu\text{M}$ ),  $\text{LTB}_4$  ( $100 \text{ nM}$ ), or fMLP ( $100 \text{ nM}$ ) for 5 min. Addition of  $130 \mu\text{M}$  cytochrome *c* was done 5 min before the addition of the stimuli. Incubations were stopped by placing the samples in an ice-water bath for 15 min. Samples were next centrifuged ( $4^{\circ}\text{C}$ ; 5 min;  $700 g$ ), and cell-free supernatants were analyzed for  $\text{O}_2^-$  production using the following formula:  $(\text{OD}_{550} - \text{OD}_{540}) \times 47.4 = \text{nmol O}_2^- / 10^6 \text{ cells/time units}$ .

### Bacterial growth and bactericidal assay

Inocula of *E. coli* or *S. aureus* were grown overnight (18 h,  $37^{\circ}\text{C}$ ) in TSB. The obtained cultures were diluted 1/100 in fresh TSB and incubated at  $37^{\circ}\text{C}$  until the  $\text{OD}_{600}$  reached 0.5. Aliquots of the culture broths ( $250 \mu\text{l}$  for *E. coli* and  $500 \mu\text{l}$  for *S. aureus*) were washed twice and then suspended in 1 ml sodium phosphate buffer (10 mM; pH 7.4) containing 1% TSB. Solutions then were diluted with the same buffer (1/3500 for *E. coli* and 1/1750 for *S. aureus*) to obtain suspensions of 10,000 CFU/ml. The resulting bacterial suspensions were then diluted with an equal volume of supernatant from activated neutrophils at  $37^{\circ}\text{C}$  for 4 h. Samples were next diluted 1/300 in sodium phosphate buffer containing 1% TSB, plated on LB agar plates, and incubated overnight to allow the growth of colonies and their enumeration.

### Epithelial cell culture and virucidal assays

For the production of HSV-1, Vero cells were cultured in M199 medium, supplemented with 10% FBS, penicillin, streptomycin, and amphotericin B. Cells were passaged by trypsinization and grown until they reached 80% confluence. Vero cells were then infected with HSV-1. When cellular lysis was almost complete (5 days), the supernatant was collected, filtered ( $0.45 \mu\text{m}$ ), and pelleted ( $30,000 g$ ; 180 min). The viral pellet was suspended in 5 ml HBSS, aliquoted, and frozen at  $-80^{\circ}\text{C}$ . HSV-1 titration was determined by a standard plaque assay on Vero cells. Viral preparations only underwent one freeze-thaw cycle. For the analysis of HSV-1 infectivity, assays were performed, as described before with slight modifications [39]. In brief, the HSV-1 stock solution was diluted in M199 medium to a final working concentration of 1200 PFU/ml and kept on ice until further use. In parallel,  $15 \mu\text{l}$  neutrophil supernatant was added to  $85 \mu\text{l}$  M199 medium and then mixed with  $50 \mu\text{l}$  of the HSV-1 working solution and incubated at  $37^{\circ}\text{C}$  for 10 min. Samples were then mixed with  $350 \mu\text{l}$  M199, and the mixture was added to each well of a 12-well plate containing 90% confluent Vero cells. The plates then were incubated for 60 min at  $37^{\circ}\text{C}$ , after which, the media were replaced with M199 containing 1.5% methylcellulose. After a 3-day incubation at  $37^{\circ}\text{C}$ , wells were washed twice with PBS, fixed with 5% formaldehyde for 10 min, then stained with 0.8% crystal violet in 50% ethanol for 2 min, and finally, washed with sterile water to allow the determination of HSV-1 infectivity by plaque count.

For the production of rRSV encoding GFP, amplification and purification were performed, as described previously [46]. In brief, amplification was done in human epidermoid cancer cell at a multiplicity of infection of 0.1 until a 50% cytopathic effect was observed. Virus was purified by ultracentrifugation on 30% sucrose cushion centrifugation at  $4^{\circ}\text{C}$  (18 h;  $8000 g$ ). RSV titration was determined by a standard plaque assay on Vero cells. Viral preparations only underwent one freeze-thaw cycle. For the analysis of RSV infectivity, treatment with neutrophil supernatants was performed, as described for HSV-1, except that DMEM medium was used. Infection of Vero cells was performed for 2 h in DMEM containing 2% FBS. The medium was then replaced with DMEM containing 1% methylcellulose and 2% FBS. Infection was pursued for 7 days, and fluorescent lysis plaques were visualized using a Typhoon apparatus (Molecular Dynamics, Sunnyvale, CA, USA).

### Statistical analyses

Variables were log-transformed to stabilize variance and analyzed with a multiple comparison using the Tukey method. Results were considered sig-


nificant if *P* values were  $<0.05$ . The data were analyzed using the statistical package program SAS version 9.1.3 (SAS Institute, Cary, NC, USA).

## RESULTS

### 2-AG and AA induce the release of antimicrobial effectors by cytochalasin B-treated neutrophils

As our initial work on human neutrophils indicated that 2-AG was stimulatory rather than inhibitory [36], we first assessed whether endocannabinoids would also induce the release of antimicrobial effectors. Neutrophil suspensions were incubated with increasing concentrations of 2-AG or AA for 5 min, and then the cell-free supernatants were assayed for their potency to impair HSV-1 or RSV infectivity using Vero cells. The supernatants of 2-AG- and AA-stimulated neutrophils inhibited HSV-1 infectivity with similar efficacies and potencies, with 50% protection at  $\sim 30 \text{ nM}$  (Fig. 1A). Additionally,  $1 \mu\text{M}$  2-AG or AA significantly decreased RSV infectivity of Vero cells by  $\sim 45\%$ , which was similar to the effect of  $100 \text{ nM}$   $\text{LTB}_4$  (Fig. 1B).

Given that 2-AG and AA levels are increased significantly during sepsis [47], we investigated whether they would also



**Figure 1. 2-AG and AA induce the release of antiviral activities.** Human neutrophil suspensions ( $2 \times 10^7$  cells/ml) in HBSS containing 1.6 mM  $\text{CaCl}_2$  were incubated with  $1 \mu\text{M}$  cytochalasin B for 15 min and then stimulated with 2-AG or AA for 5 min. Incubations were stopped by placing the samples in an ice-water bath. Cell-free supernatants were diluted in M199 medium (10:90) and incubated with (A) HSV-1 or (B) RSV for 10 min before infection, as described in Materials and Methods. Data are the mean ( $\pm$ SEM) of four experiments, each performed in duplicate. Statistical analyses were done using mixed-effects ANOVA, followed by the Tukey a posteriori test and were considered significant when *P* values were  $<0.05$ . \*Statistically significant difference compared with vehicle (DMSO).

impair bacterial growth. We consequently performed another series of experiments in which the supernatants of 2-AG- and AA-treated neutrophils were incubated with exponentially growing *E. coli* or *S. aureus* suspensions. 2-AG and AA induced the release of a bactericidal activity from neutrophils, although the EC<sub>50</sub> were one order of magnitude higher than what we observed with HSV-1 (Fig. 2). The maximal effects of 2-AG and AA were obtained with 3 μM 2-AG or AA, which inhibited the growth of *S. aureus* and *E. coli* by ~95% and ~85%, respectively. Importantly, the low concentration of LTB<sub>4</sub>, AA, or 2-AG that we used did not impact virus infectivity or bacterial growth [48, 49].


### 2-AG and AA induce the release of α-defensins and LL-37

As the antimicrobial effects of AA- and 2-AG-activated neutrophil supernatants were observed during short-term incubations (5 min), we postulated that the mediators involved were rapidly produced or stored in neutrophil granules. 2-AG, AA, and LTB<sub>4</sub> were poor inducers of O<sub>2</sub><sup>-</sup> release compared with fMLP


(Fig. 3A). Indeed, 100 nM fMLP induced the release of O<sub>2</sub><sup>-</sup>, 5× greater than that observed with LTB<sub>4</sub>, 2-AG, or AA. Moreover, the NADPH oxidase inhibitor DPI, which blocked O<sub>2</sub><sup>-</sup> production (Fig. 3A), did not prevent the effects of 2-AG and AA on bacterial growth (data not shown). In contrast, 2-AG and AA induced an important release of α-defensins (Fig. 3B) and LL-37 (Fig. 3C) in a concentration-dependent manner. This began at a 2-AG or AA concentration of 300 nM, which is also the concentration at which supernatants begin to exert their bactericidal effects (Fig. 2) and was maximal at 3 μM. Interestingly, this mimicked the dose-response curves obtained for the biosynthesis of LTB<sub>4</sub> induced by 2-AG or AA [36]. The release of antimicrobial peptides induced by 2-AG and AA was rapid (Figs. 3D and E), with most of the peptides released within 2 min. AEA, the GPR55 agonist (and CB<sub>1</sub> antagonist) AM-251, as well as 2-AG ether (a nonhydrolyzable form of 2-AG) did not induce the release of α-defensin or LL-37 (Figs. 3B and C). The amounts of antimicrobial peptides released upon neutrophil activation were different for both classes of peptides. Indeed, whereas α-defensins were detected in the microgram range, LL-37 was found in the nanogram range (~250:1 ratio). In an attempt to dissect the contribution of α-defensins and LL-37 in the antimicrobial effects that we observed, additional experiments were performed by treating neutrophil supernatants with commercially available staphylokinase and aureolysin to impair the efficacy of α-defensins and LL-37. This strategy was, however, unsuccessful, as both protein preparations directly inhibited the growth of our bacterial suspensions (data not shown). We, nonetheless, investigated the potency of purified α-defensins and LL-37 on bacterial growth in our experimental model. Purified peptides effectively inhibited the growth of *E. coli* (Fig. 3F), with LL-37 being more potent by one order of magnitude. Essentially similar results were obtained for *S. aureus* (data not shown). Interestingly, when 10 μg/ml α-defensins were combined with 40 ng/ml LL-37 (250:1 ratio), the antimicrobial peptides prevented the growth of *E. coli* suspension in a synergistic manner (Fig. 3G).

### CBs are not involved in the 2-AG-induced release of antimicrobial peptides

The results obtained using AEA and 2-AG ether (Fig. 3B and C), which activate CBs and GPR55 [50–55], suggested that the effects of 2-AG were likely independent of GPR55 or CB activation. The expression of CBs by neutrophils is controversial. Neutrophils were reported to express the CB<sub>2</sub> receptor [56–59], whereas others [27] and we [36] reported otherwise. Interestingly, the absence of CB<sub>2</sub> receptor mRNA by human neutrophils coincided with the removal of contaminating eosinophils. This prompted us to determine the expression of the CB<sub>2</sub> receptor in isolated granulocytes (which many research groups use as purified neutrophils), eosinophil-depleted neutrophils, and eosinophils. As shown in Fig. 4, CB<sub>2</sub> receptor mRNA expression was detected by RT-PCR in isolated granulocytes and eosinophils, in sharp contrast to purified (eosinophil-depleted) neutrophils. Additional experiments using qPCR (Fig. 4E) also yielded similar results: the removal of contaminating eosinophils significantly decreased the CB<sub>2</sub> mRNA



**Figure 2. 2-AG and AA induce the release of antibacterial activities.** Human neutrophils ( $2 \times 10^7$  cells/ml) in HBSS containing 1.6 mM CaCl<sub>2</sub> were incubated with 1 μM cytochalasin B for 15 min and then stimulated with (A) AA or (B) 2-AG for 5 min. Incubations were stopped by placing the samples in an ice-water bath and then centrifuged. Cell-free supernatants were incubated (1:1) with exponentially growing *E. coli* or *S. aureus* suspensions (10,000 CFU/ml) in sodium phosphate buffer containing 1% TSB for 4 h at 37°C. Samples then were spread on LB agar plates and incubated overnight at 37°C, followed by CFU enumeration. The results represent the mean ( $\pm$ SEM) of four independent experiments, each performed in triplicate. Vehicle represents an amount of DMSO that equals the volume used in each experiment involving 2-AG or AA.



**Figure 3. 2-AG and AA induce the release of antimicrobial factors.** (A) Human neutrophils ( $2 \times 10^7$  cells/ml) in HBSS containing 1.6 mM  $\text{CaCl}_2$  were incubated with 1  $\mu\text{M}$  cytochalasin B for 15 min and then stimulated with 3  $\mu\text{M}$  2-AG, 3  $\mu\text{M}$  AA, 100 nM  $\text{LTB}_4$ , or 100 nM fMLP for 5 min in the presence or absence of 10  $\mu\text{M}$  DPI. Incubation was stopped by placing the samples in an ice-water bath and analyzed for  $\text{O}_2^-$  production, as described in Materials and Methods. (B and C) Human neutrophils ( $2 \times 10^7$  cells/ml) in HBSS containing 1.6 mM  $\text{CaCl}_2$  were stimulated with 2-AG, AA, 2-AG ether, AEA, or AM-251 at the indicated concentration for 5 min. Incubations were stopped by placing the samples in an ice-water bath, and then cell-free supernatants were analyzed for their content in  $\alpha$ -defensins or LL-37, as described in Materials and Methods. (D and E) Human neutrophils ( $2 \times 10^7$  cells/ml) in HBSS containing 1.6 mM  $\text{CaCl}_2$  were stimulated with 3  $\mu\text{M}$  2-AG or AA for the indicated times. Incubations were stopped by placing the samples in an ice-water bath, and then the cell-free supernatants were analyzed for their content in  $\alpha$ -defensins or LL-37, as described in Materials and Methods. (F) Purified LL-37 or  $\alpha$ -defensins were incubated with exponentially growing *E. coli* suspensions (10,000 CFU/ml) in sodium phosphate buffer containing 1% TSB for 4 h at 37°C. (G) Purified LL-37 (40 ng/ml),  $\alpha$ -defensins (10  $\mu\text{g}/\text{ml}$ ), or both were incubated with exponentially growing *E. coli* suspensions (10,000 CFU/ml) in sodium phosphate buffer containing 1% TSB for 4 h at 37°C. (F and G) Samples were diluted 1/300 in incubation medium, plated on LB agar plates, and incubated overnight at 37°C to allow CFU enumeration. (A–G) The data represent the mean ( $\pm$ SEM) of at least three independent experiments, each performed in duplicate.



phosphate buffer containing 1% TSB for 4 h at 37°C. (G) Purified LL-37 (40 ng/ml),  $\alpha$ -defensins (10  $\mu\text{g}/\text{ml}$ ), or both were incubated with exponentially growing *E. coli* suspensions (10,000 CFU/ml) in sodium phosphate buffer containing 1% TSB for 4 h at 37°C. (F and G) Samples were diluted 1/300 in incubation medium, plated on LB agar plates, and incubated overnight at 37°C to allow CFU enumeration. (A–G) The data represent the mean ( $\pm$ SEM) of at least three independent experiments, each performed in duplicate.

signal found in granulocytes. Importantly, the expression of  $\text{CB}_2$  receptor mRNA by human eosinophils was  $\sim 100$ -fold higher than that observed with highly purified neutrophils. We also undertook a series of experiments, in which human neutrophils were pretreated with the  $\text{CB}_1$  receptor antagonist O-2050 or the  $\text{CB}_2$  antagonist SR144528. Both antagonists did not prevent the bactericidal effects of 2-AG (Fig. 5A) nor did they prevent the release of antimicrobial peptides (Fig. 5B and C). Additionally, AEA and the GPR55 agonist (and  $\text{CB}_1$  antagonist) AM-251 did not inhibit nor enhance the 2-AG-induced release of  $\alpha$ -defensins or LL-37. Altogether, the lack of effect of AEA and 2-AG ether combined with the lack of efficacy of  $\text{CB}$  antagonists to block the 2-AG-induced antimicrobial peptide release and bactericidal effect indicate that these phenomena are likely independent of  $\text{CB}_1$ ,  $\text{CB}_2$ , or GPR55 activation.

#### 2-AG hydrolysis, AA, and $\text{LTB}_4$ biosynthesis are involved in the antimicrobial effects of 2-AG

The similarity between the effects induced by 2-AG and AA and the absence of response of AEA and 2-AG ether sug-

gested that the effects of 2-AG and AA were mediated through their metabolism. Importantly, 2-AG and AA induce a robust biosynthesis of  $\text{LTB}_4$  by human neutrophils [36, 60], and  $\text{LTB}_4$  is an important regulator of host defense [38–42, 61]. Blockade of 2-AG hydrolysis to AA (MAFP),  $\text{LTB}_4$  biosynthesis (MK-0591), or  $\text{BLT}_1$  activation (CP 105,696) inhibited the effects of 2-AG on the release of antimicrobial activity (Fig. 6A) and antimicrobial peptides (Figs. 6A–C). LT modifiers, but not MAFP, also prevented the effect of AA on antimicrobial peptide release and the antimicrobial effects observed. Importantly, the release of  $\alpha$ -defensins and LL-37, induced by fMLP, was not affected by any of the tested compounds. These results demonstrate that the release antimicrobial effects of 2-AG and AA relies on de novo  $\text{LTB}_4$  biosynthesis, as opposed to the effects of fMLP. They clearly underscore the essential role of  $\text{LTB}_4$  in the release of the antimicrobial activity by 2-AG and AA. Moreover, they underline the potential of 2-AG as a source of AA for neutrophils in vivo.




**Figure 4. Expression of CB<sub>2</sub> by granulocytes, eosinophil-depleted neutrophils, and eosinophils.** Granulocytes (A) were purified further into neutrophils (CD16<sup>+</sup>; B) and eosinophils (CD16<sup>-</sup>; C) and then stained with Diff-Quik. Total RNA was extracted from the cell pellets, and amplification of the CB<sub>2</sub> receptor mRNA by (D) RT-PCR or by (E) RT-qPCR was performed, as described in Materials and Methods. (D) The data represent a typical RT-PCR result obtained using the mRNA from cells of the same donor. (E) Data are the mean (±SEM) of six independent experiments, each performed in triplicate. Statistical analyses were done using mixed-effects ANOVA, followed by the Tukey a posteriori test. 18S refers to 18S rRNA and is used as an expression control.

**DISCUSSION**


In the present study, we evaluated the effects of AEA, 2-AG, and AA on the activation of neutrophil functions related to host defense. We found that in contrast to AEA, very low (mid-nanometer) concentrations of 2-AG and AA induce the release of antimicrobial effectors against *S. aureus*, *E. coli*, HSV-1, and RSV. The activation of neutrophils by 2-AG and AA was associated with: 1) the release of α-defensins and LL-37; 2) a lack of CB involvement; and 3) an essential role of endogenous LTB<sub>4</sub>

and BLT<sub>1</sub> activation. This suggests that low 2-AG concentration possibly plays an important role in host defense by promoting human neutrophil functions.

Plasma and tissue endocannabinoid levels are usually in the low nanomolar range [62, 63] but increase following cell activation. Many inflammatory mediators, present at infectious sites, such as LPS, platelet-activating factor, and M-CSF, induce the biosynthesis of endocannabinoids by leukocytes [64–67]. In this respect, endocannabinoid levels in sepsis and inflamed



**Figure 5. The 2-AG-mediated bacterial killing and antimicrobial peptide release are independent of CB activation.** (A) Neutrophil suspensions (2 × 10<sup>7</sup> cells/ml) in HBSS containing 1.6 mM CaCl<sub>2</sub> were incubated with 1 μM cytochalasin B for 15 min and then stimulated with 1 μM 2-AG for 5 min. Incubations were stopped by adding 1 vol ice-cold buffer, immediately placing the samples in an ice-water bath for 5 min, and then centrifuged. Cell-free supernatants then were incubated with exponentially growing *E. coli* or *S. aureus* for 4 h and then plated on LB agar plates overnight to allow CFU quantification, as described in Materials and Methods. (B and C) Neutrophil suspensions (2 × 10<sup>7</sup> cells/ml) in HBSS containing 1.6 mM CaCl<sub>2</sub> were incubated with 1 μM cytochalasin B for 15 min and then stimulated with 1 μM 2-AG for 5 min. Incubations were stopped by adding 1 vol cold incubation buffer and then rapidly centrifuged. Supernatants then were assessed for their content in (B) α-defensins 1–3 and (C) LL-37 by ELISA, according to the manufacturer’s instructions. Addition of 1 μM AEA, the GPR55 agonist (and CB<sub>1</sub> antagonist) AM-251, the CB<sub>1</sub> antagonist O-2050, or the CB<sub>2</sub> antagonist SR144528 was done 5 min before stimulating neutrophils with 2-AG in all experimental settings. The data represent the mean (±SEM) of three independent experiments performed in duplicate.



**Figure 6. Involvement of LTB<sub>4</sub> in the effects of 2-AG and AA on bacterial growth and antimicrobial peptide release by neutrophils.** (A) Neutrophil suspensions ( $2 \times 10^7$  cells/ml) in HBSS containing 1.6 mM CaCl<sub>2</sub> were incubated with 1  $\mu$ M cytochalasin B for 15 min and then stimulated with 3  $\mu$ M 2-AG for 5 min. Incubations were stopped by placing the samples in an ice-water bath and then centrifuged. Cell-free supernatants were incubated with exponentially growing *E. coli* or *S. aureus* for 4 h and then plated on LB agar plates overnight to allow CFU quantification, as described in Materials and Methods. (B and C) Neutrophil suspensions ( $2 \times 10^7$  cells/ml) in HBSS containing 1.6 mM CaCl<sub>2</sub> were incubated with 1  $\mu$ M cytochalasin B for 15 min and then stimulated with 3  $\mu$ M 2-AG, 3  $\mu$ M AA, 100 nM LTB<sub>4</sub>, or 100 nM fMLP for 5 min. Incubations were stopped by adding 1 vol cold incubation buffer and then rapidly centrifuged. Supernatants were next assessed for their content in (B)  $\alpha$ -defensins 1–3 and (C) LL-37 by ELISA, according to the manufacturer's instructions. The addition of the BLT<sub>1</sub> antagonist CP 105,696 (100 nM), the FLAP antagonist MK-0591 (100 nM), and the 2-AG hydrolysis inhibitor MAFP (30 nM) was done 5 min prior to the stimulation with 2-AG, AA, LTB<sub>4</sub>, or fMLP in all experimental settings. The results represent the mean ( $\pm$ SEM) of at least three independent experiments, each performed in duplicate.

tissues are in the micromolar range [47, 68], well above the EC<sub>50</sub> that we observed in this study (Figs. 1 and 2). Importantly, experiments performed with HSV-1 and RSV were done in the presence of only 10% (v/v) of neutrophil supernatants, possibly underestimating the efficacy of 2-AG and AA by up to one order of magnitude.

Studies investigating the involvement of CBs at regulating neutrophil functions are limited. Moreover, inconsistencies are found regarding the expression of the CB receptors [27, 36, 56, 57, 69–77]. Importantly, studies that reported a lack of CB<sub>2</sub> were performed using cell preparations in which contaminating eosinophils were removed [27, 36]. The comparative experiments among granulocytes (neutrophils and eosinophils), neutrophils, and eosinophils, which we provided here, demonstrate that >95% of CB<sub>2</sub> mRNA for CB<sub>2</sub> originates from eosinophils rather than neutrophils (Fig. 4). The 100-fold higher CB<sub>2</sub> receptor expression (mRNA) that we observed in human eosinophils indicates that even a 1% contamination of neutrophil suspensions with eosinophils is enough to yield a false-positive signal when performing RT-PCR or qPCR analyses. Furthermore, the inefficacy of other endocannabinoids (AEA, 2-AG ether) or CB antagonists to, respectively, mimic or block the effects of 2-AG supports an activation mechanism independent of CB receptors.

Following its uptake, 2-AG can be hydrolyzed to AA by serine hydrolases, such as monoacylglycerol lipase, or metabolized into other bioactive lipids by eicosanoid biosynthetic enzymes [34, 35, 78–81]. The data presented here (Fig. 5) indicate that 2-AG and AA induce the release of antimicrobial activities through their metabolism into LTB<sub>4</sub> and the activation of BLT<sub>1</sub>, in agreement with our previous study [36]. This again supports the physiological role of LTB<sub>4</sub> in host defense. Indeed, LTB<sub>4</sub> enhances host defense in vivo, promoting antimicrobial peptide release and enhancing phagocyte functions through BLT<sub>1</sub> receptor activation [39, 40].

AA is usually esterified at the *sn*-2 position of glycerophospholipid. One of the dogmata regarding AA release is that upon cell activation, the group IVA PLA<sub>2</sub> translocates to membranes, where it releases AA. Interestingly, other PLA<sub>2</sub>, notably the secreted PLA<sub>2</sub> groups V, X, and XII, are also participating in AA release [82]. The important impact of exogenously added AA on the release of antimicrobial peptides and antimicrobial effects that we observed indicates that secreted PLA<sub>2</sub> might also play an important role in the regulation of host defense. This, however, fosters additional studies to delineate the putative role of the secreted PLA<sub>2</sub> in these processes.

We also attempted to delineate the exact contribution of some antimicrobial products. Our data indicate that 2-AG and AA induced a modest production of ROS compared with fMLP and that the inhibition of NADPH oxidase with DPI did not blunt the effect of 2-AG and AA (Fig. 3, and data not shown). Interestingly, LL-37 and  $\alpha$ -defensins were documented to mediate the LTB<sub>4</sub>-induced antimicrobial effects of neutrophils [8, 39]. Our data show that there is an  $\sim$ 250:1 ratio between  $\alpha$ -defensins and LL-37 release following the activation of human neutrophils by 2-AG or AA. Furthermore, our data indicate that LL-37 is more potent than  $\alpha$ -defensins against *E. coli* and *S. aureus* by one order of magnitude (ED<sub>50</sub> of 1 vs. 10

$\mu\text{g/ml}$ ). Importantly, we provided evidence that  $\alpha$ -defensins and LL-37 acted synergistically rather than redundantly (Fig. 3G) in agreement with a previous study [83]. This suggests that the bactericidal effect of 2-AG and AA is likely the consequence of LL-37 and  $\alpha$ -defensins. Interestingly, the inhibitory effect of 2-AG- and AA-stimulated neutrophil supernatants on HSV-1 infectivity does not correlate with the release of LL-37 or  $\alpha$ -defensins (Figs. 1 and 3). This suggests that other soluble mediators might also participate in the virucidal effect of 2-AG- and AA-stimulated neutrophil supernatants and fosters additional studies.

Cytochalasin B acts by disrupting the actin cytoskeleton, which enhances many neutrophil functions, including degranulation. Cytoskeleton-disrupting agents are not necessary in vivo, as adherence to endothelium, which is linked to cytoskeleton rearrangement, is sufficient to prime neutrophils and promote the release of granule components (reviewed in ref. [39]). To better mimic the fate of in vivo neutrophils, we treated our neutrophil suspensions with 1  $\mu\text{M}$  cytochalasin B to enhance their cellular responses. In the absence of cytochalasin B, only a minimal release of LL-37 and  $\alpha$ -defensins was observed (data not shown).

Finally, our experiments were performed under serum-free conditions, given that serum can trap fatty acids. For example, the use of serum or BSA has long been used to analyze AA release by stimulated cells ex vivo. Moreover, the incubation of isolated neutrophils in plasma results in the trapping of de novo-synthesized LTA<sub>4</sub> [84]. Nonetheless, LTB<sub>4</sub> can be found in activated whole blood under many circumstances. In our own hands, we still observed a stimulatory effect of 2-AG and AA, with up to 2% BSA (data not shown), which represents the protein content of an aqueous solution containing 5% serum [85]. We favored using BSA over plasma or serum to avoid the stimulatory effect that TGF- $\beta$  has on the LT pathway [86]. That being said, AA-specific secreted PLA<sub>2</sub> enzymes have many biological functions involving eicosanoids, albeit they release AA in the extracellular space.

In conclusion, we provide evidence that 2-AG and AA are potential regulators of human neutrophil functions associated to host defense. Importantly, this occurred at physiological (nanomolar) concentrations of 2-AG and AA and was associated with the release of LL-37 and  $\alpha$ -defensins from cytochalasin B-treated neutrophils. Numerous events associated with the innate and adaptive immune responses are linked to antimicrobial peptides: they recruit and activate leukocytes [5–13], the complement cascade [87], and the phagocytosis by macrophages. Consequently, our data support that 2-AG and AA may be important physiological regulators of the innate and adaptive immune responses in humans. Additional studies will be needed to establish the roles of 2-AG and AA as regulators of neutrophil-mediated innate immunity in vivo.

## AUTHORSHIP

F.C., C.T., M-C.L., X.G., S.P., L.B., and V.P. performed experiments. F.C., C.T., L.F., N.G., and N.F. designed the experiments. F.C. and N.F. wrote the paper. All authors reviewed the paper.

## ACKNOWLEDGMENTS

This work was supported by grants to N.F. from the CIHR and the Natural Sciences and Engineering Research Council of Canada. F.C. was the recipient of a doctoral training award from the CIHR. N.F. and N.G. are the recipients of scholarships from the Fonds de Recherche du Québec-Santé.

## REFERENCES

- Ganz, T., Selsted, M. E., Szklarek, D., Harwig, S. S., Daher, K., Bainton, D. F., Lehrer, R. I. (1985) Defensins. Natural peptide antibiotics of human neutrophils. *J. Clin. Invest.* **76**, 1427–1435.
- Daher, K. A., Selsted, M. E., Lehrer, R. I. (1986) Direct inactivation of viruses by human granulocyte defensins. *J. Virol.* **60**, 1068–1074.
- Smeianov, V., Scott, K., Reid, G. (2000) Activity of cecropin P1 and FA-LL-37 against urogenital microflora. *Microbes Infect.* **2**, 773–777.
- Howell, M. D., Jones, J. F., Kisich, K. O., Streib, J. E., Gallo, R. L., Leung, D. Y. (2004) Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. *J. Immunol.* **172**, 1763–1767.
- Grigat, J., Soruri, A., Forssmann, U., Riggert, J., Zwirner, J. (2007) Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human  $\alpha$ -defensin family. *J. Immunol.* **179**, 3958–3965.
- De, Y., Chen, Q., Schmidt, A. P., Anderson, G. M., Wang, J. M., Wooters, J., Oppenheim, J. J., Chertov, O. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. *J. Exp. Med.* **192**, 1069–1074.
- Niyonsaba, F., Iwabuchi, K., Someya, A., Hirata, M., Matsuda, H., Ogawa, H., Nagaoka, I. (2002) A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. *Immunology* **106**, 20–26.
- Wan, M., Sabirsh, A., Wetterholm, A., Agerberth, B., Haeggstrom, J. Z. (2007) Leukotriene B<sub>4</sub> triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. *FASEB J.* **21**, 2897–2905.
- Chaly, Y. V., Paleolog, E. M., Kolesnikova, T. S., Tikhonov, I. I., Petratchenko, E. V., Voitenok, N. N. (2000) Neutrophil  $\alpha$ -defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. *Eur. Cytokine Netw.* **11**, 257–266.
- Khine, A. A., Del, S. L., Vaschetto, R., Voglis, S., Tullis, E., Slutsky, A. S., Downey, G. P., Zhang, H. (2006) Human neutrophil peptides induce interleukin-8 production through the P2Y<sub>6</sub> signaling pathway. *Blood* **107**, 2936–2942.
- Koczulla, R., von, D. G., Kupatt, C., Krotz, F., Zahler, S., Gloe, T., Issbrucker, K., Unterberger, P., Zaiou, M., Lebherz, C., Karl, A., Raake, P., Pfosser, A., Boekstegers, P., Welsch, U., Hiemstra, P. S., Vogelmeier, C., Gallo, R. L., Clauss, M., Bals, R. (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J. Clin. Invest.* **111**, 1665–1672.
- Niyonsaba, F., Someya, A., Hirata, M., Ogawa, H., Nagaoka, I. (2001) Evaluation of the effects of peptide antibiotics human  $\beta$ -defensin-1/-2 and LL-37 on histamine release and prostaglandin D<sub>2</sub> production from mast cells. *Eur. J. Immunol.* **31**, 1066–1075.
- Scott, M. G., Davidson, D. J., Gold, M. R., Bowdish, D., Hancock, R. E. (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *J. Immunol.* **169**, 3883–3891.
- Klein, T. W., Newton, C., Friedman, H. (1994) Resistance to *Legionella pneumophila* suppressed by the marijuana component, tetrahydrocannabinol. *J. Infect. Dis.* **169**, 1177–1179.
- Cabral, G. A., Marciano-Cabral, F. (2004) Cannabinoid-mediated exacerbation of brain infection by opportunistic amoebae. *J. Neuroimmunol.* **147**, 127–130.
- Morahan, P. S., Klykken, P. C., Smith, S. H., Harris, L. S., Munson, A. E. (1979) Effects of cannabinoids on host resistance to *Listeria monocytogenes* and herpes simplex virus. *Infect. Immun.* **23**, 670–674.
- Mishkin, E. M., Cabral, G. A. (1985)  $\Delta$ -9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. *J. Gen. Virol.* **66**, 2539–2549.
- Friedman, M., Cepero, M. L., Klein, T., Friedman, H. (1986) Suppressive effect of  $\Delta$ -9-tetrahydrocannabinol in vitro on phagocytosis by murine macrophages. *Proc. Soc. Exp. Biol. Med.* **182**, 225–228.
- Lopez-Cepero, M., Friedman, M., Klein, T., Friedman, H. (1986) Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro. *J. Leukoc. Biol.* **39**, 679–686.
- Blanchard, D. K., Newton, C., Klein, T. W., Stewart, W. E., Friedman, H. (1986) In vitro and in vivo suppressive effects of  $\Delta$ -9-tetrahydrocannabinol on interferon production by murine spleen cells. *Int. J. Immunopharmacol.* **8**, 819–824.
- Smith, S. R., Terminelli, C., Denhardt, G. (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory

- cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. *J. Pharmacol. Exp. Ther.* **293**, 136–150.
22. Newton, C. A., Klein, T. W., Friedman, H. (1994) Secondary immunity to *Legionella pneumophila* and Th1 activity are suppressed by  $\Delta^9$ -tetrahydrocannabinol injection. *Infect. Immun.* **62**, 4015–4020.
  23. Yuan, M., Kiertscher, S. M., Cheng, Q., Zoumalan, R., Tashkin, D. P., Roth, M. D. (2002)  $\Delta^9$ -Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. *J. Neuroimmunol.* **133**, 124–131.
  24. Kishimoto, S., Gokoh, M., Oka, S., Muramatsu, M., Kajiwara, T., Waku, K., Sugiura, T. (2003) 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB<sub>2</sub> receptor-dependent mechanism. *J. Biol. Chem.* **278**, 24469–24475.
  25. Kishimoto, S., Muramatsu, M., Gokoh, M., Oka, S., Waku, K., Sugiura, T. (2005) Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. *J. Biochem.* **137**, 217–223.
  26. Maestroni, G. J. (2004) The endogenous cannabinoid 2-arachidonoylglycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. *FASEB J.* **18**, 1914–1916.
  27. Oka, S., Ikeda, S., Kishimoto, S., Gokoh, M., Yanagimoto, S., Waku, K., Sugiura, T. (2004) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EOL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. *J. Leukoc. Biol.* **76**, 1002–1009.
  28. Shiratsuchi, A., Watanabe, I., Yoshida, H., Nakanishi, Y. (2008) Involvement of cannabinoid receptor CB<sub>2</sub> in dextrin-I-mediated macrophage phagocytosis. *Immunol. Cell Biol.* **86**, 179–184.
  29. Stefano, G. B., Bilfinger, T. V., Rialas, C. M., Deutsch, D. G. (2000) 2-Arachidonoyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. *Pharmacol. Res.* **42**, 317–322.
  30. Gokoh, M., Kishimoto, S., Oka, S., Metani, Y., Sugiura, T. (2005) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. *FEBS Lett.* **579**, 6473–6478.
  31. Kishimoto, S., Kobayashi, Y., Oka, S., Gokoh, M., Waku, K., Sugiura, T. (2004) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. *J. Biochem.* **135**, 517–524.
  32. Sugamura, K., Sugiyama, S., Nozaki, T., Matsuzawa, Y., Izumiya, Y., Miyata, K., Nakayama, M., Kaikita, K., Obata, T., Takeya, M., Ogawa, H. (2009) Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. *Circulation* **119**, 28–36.
  33. Lau, A. H., Chow, S. S. (2003) Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. *Eur. J. Pharmacol.* **464**, 229–235.
  34. Yu, M., Ives, D., Ramesha, C. S. (1997) Synthesis of prostaglandin E<sub>2</sub> ethanolamide from anandamide by cyclooxygenase-2. *J. Biol. Chem.* **272**, 21181–21186.
  35. Kozak, K. R., Rowlinson, S. W., Marnett, L. J. (2000) Oxygenation of the endocannabinoid, 2-arachidonoylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. *J. Biol. Chem.* **275**, 33744–33749.
  36. Chouinard, F., Lefebvre, J. S., Navarro, P., Bouchard, L., Ferland, C., Lalancette-Hebert, M., Marsolais, D., Laviolette, M., Flamand, N. (2011) The endocannabinoid 2-arachidonoylglycerol activates human neutrophils: critical role of its hydrolysis and de novo leukotriene B<sub>4</sub> biosynthesis. *J. Immunol.* **186**, 3188–3196.
  37. Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., Cravatt, B. F. (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *Science* **334**, 809–813.
  38. Coffey, M. J., Phare, S. M., Peters-Golden, M. (2004) Role of leukotrienes in killing of *Mycobacterium bovis* by neutrophils. *Prostaglandins Leukot. Essent. Fatty Acids* **71**, 185–190.
  39. Flamand, L., Tremblay, M. J., Borgeat, P. (2007) Leukotriene B<sub>4</sub> triggers the in vitro and in vivo release of potent antimicrobial agents. *J. Immunol.* **178**, 8036–8045.
  40. Mancuso, P., Nana-Sinkam, P., Peters-Golden, M. (2001) Leukotriene B<sub>4</sub> augments neutrophil phagocytosis of *Klebsiella pneumoniae*. *Infect. Immun.* **69**, 2011–2016.
  41. Gaudreault, E., Gosselin, J. (2007) Leukotriene B<sub>4</sub>-mediated release of antimicrobial peptides against cytomegalovirus is BLT<sub>1</sub> dependent. *Viral Immunol.* **20**, 407–420.
  42. Gaudreault, E., Gosselin, J. (2008) Leukotriene B<sub>4</sub> induces release of antimicrobial peptides in lungs of virally infected mice. *J. Immunol.* **180**, 6211–6221.
  43. Boyum, A. (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. *Scand. J. Clin. Lab. Invest. Suppl.* **97**, 77–89.
  44. Flamand, N., Boudreault, S., Picard, S., Austin, M., Surette, M. E., Plante, H., Krump, E., Vallee, M. J., Gilbert, C., Naccache, P., Laviolette, M., Borgeat, P. (2000) Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. *Am. J. Respir. Crit. Care Med.* **161**, S88–S94.
  45. Dahlgren, C., Karlsson, A. (1999) Respiratory burst in human neutrophils. *J. Immunol. Methods* **232**, 3–14.
  46. Yoboua, F., Martel, A., Duval, A., Mukawera, E., Grandvaux, N. (2010) Respiratory syncytial virus-mediated NF- $\kappa$ B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK $\beta$ . *J. Virol.* **84**, 7267–7277.
  47. Kase, Y., Obata, T., Okamoto, Y., Iwai, K., Saito, K., Yokoyama, K., Takinami, M., Tanifuji, Y. (2008) Removal of 2-arachidonoylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. *Ther. Apher. Dial.* **12**, 374–380.
  48. Knapp, H. R., Melly, M. A. (1986) Bactericidal effects of polyunsaturated fatty acids. *J. Infect. Dis.* **154**, 84–94.
  49. Leu, G. Z., Lin, T. Y., Hsu, J. T. (2004) Anti-HCV activities of selective polyunsaturated fatty acids. *Biochem. Biophys. Res. Commun.* **318**, 275–280.
  50. Waldeck-Weiermair, M., Zoratti, C., Osibow, K., Balenga, N., Goessnitzer, E., Waldhoer, M., Malli, R., Graier, W. F. (2008) Integrin clustering enables anandamide-induced Ca<sup>2+</sup> signaling in endothelial cells via GPR55 by protection against CB<sub>1</sub>-receptor-triggered repression. *J. Cell Sci.* **121**, 1704–1717.
  51. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N. O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., Greasley, P. J. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. *Br. J. Pharmacol.* **152**, 1092–1101.
  52. Shoemaker, J. L., Joseph, B. K., Ruckle, M. B., Mayeux, P. R., Prather, P. L. (2005) The endocannabinoid noladin ether acts as a full agonist at human CB<sub>2</sub> cannabinoid receptors. *J. Pharmacol. Exp. Ther.* **314**, 868–875.
  53. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., Mechoulam, R. (2001) 2-Arachidonoyl glyceryl ether, an endogenous agonist of the cannabinoid CB<sub>1</sub> receptor. *Proc. Natl. Acad. Sci. USA* **98**, 3662–3665.
  54. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **258**, 1946–1949.
  55. Munro, S., Thomas, K. L., Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. *Nature* **365**, 61–65.
  56. Kurihara, R., Tohyama, Y., Matsusaka, S., Naruse, H., Kinoshita, E., Tsujioka, T., Katsumata, Y., Yamamura, H. (2006) Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. *J. Biol. Chem.* **281**, 12908–12918.
  57. Balenga, N. A., Aflaki, E., Kargl, J., Platzer, W., Schroder, R., Blattermann, S., Kostenis, E., Brown, A. J., Heinemann, A., Waldhoer, M. (2011) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. *Cell Res.* **21**, 1452–1469.
  58. Galiegue, S., Mary, S., Marchand, J., Dussosoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur. J. Biochem.* **232**, 54–61.
  59. Small-Howard, A. L., Shimoda, L. M., Adra, C. N., Turner, H. (2005) Anti-inflammatory potential of CB<sub>1</sub>-mediated cAMP elevation in mast cells. *Biochem. J.* **388**, 465–473.
  60. Surette, M. E., Krump, E., Picard, S., Borgeat, P. (1999) Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A<sub>2A</sub> receptor agonists and crucial role of autocrine activation by leukotriene B<sub>4</sub>. *Mol. Pharmacol.* **56**, 1055–1062.
  61. Serezani, C. H., Aronoff, D. M., Jancar, S., Peters-Golden, M. (2005) Leukotriene B<sub>4</sub> mediates p47phox phosphorylation and membrane translocation in polyunsaturated fatty acid-stimulated neutrophils. *J. Leukoc. Biol.* **78**, 976–984.
  62. Thomas, A., Hopfgartner, G., Giroud, C., Staub, C. (2009) Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. *Rapid Commun. Mass Spectrom.* **23**, 629–638.
  63. Quercioli, A., Pataky, Z., Vincenti, G., Makoundou, V., Di, M., V. Montecucco, F., Carballo, S., Thomas, A., Staub, C., Steffens, S., Seimbille, Y., Golay, A., Ratib, O., Harsch, E., Mach, F., Schindler, T. H. (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. *Eur. Heart J.* **32**, 1369–1378.
  64. Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J., Schmid, H. H. (2001) Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. *FASEB J.* **15**, 2171–2178.
  65. Carrier, E. J., Kearns, C. S., Barkmeier, A. J., Brees, N. M., Yang, W., Nithipatikom, K., Pfister, S. L., Campbell, W. B., Hillard, C. J. (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonoylglycerol, which increases proliferation via a CB<sub>2</sub> receptor-dependent mechanism. *Mol. Pharmacol.* **65**, 999–1007.
  66. Pestonjamp, V. K., Burstein, S. H. (1998) Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. *Biochim. Biophys. Acta* **1394**, 249–260.

67. Rouzer, C. A., Marnett, L. J. (2005) Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. *J. Biol. Chem.* **280**, 26690–26700.
68. Montecucco, F., Lenglet, S., Braunersreuther, V., Burger, F., Pelli, G., Bertolotto, M., Mach, F., Steffens, S. (2009) CB<sub>2</sub> cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. *J. Mol. Cell. Cardiol.* **46**, 612–620.
69. Murikinati, S., Juttler, E., Keinert, T., Ridder, D. A., Muhammad, S., Waibler, Z., Ledent, C., Zimmer, A., Kalinke, U., Schwaninger, M. (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. *FASEB J.* **24**, 788–798.
70. Batkai, S., Osei-Hyiaman, D., Pan, H., El-Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., Harvey-White, J., Jafri, A., Haskó, G., Huffman, J. W., Gao, B., Kunos, G., Pacher, P. (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. *FASEB J.* **21**, 1788–1800.
71. Karsak, M., Gaffal, E., Date, R., Wang-Eckhardt, L., Rehnelt, J., Petrosino, S., Starowicz, K., Steuder, R., Schlicker, E., Cravatt, B., Mechoulam, R., Buettner, R., Werner, S., Di Marzo, V., Tüting, T., Zimmer, A. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. *Science* **316**, 1494–1497.
72. Csóka, B., Németh, Z. H., Mukhopadhyay, P., Spolarics, Z., Rajesh, M., Federici, S., Deitch, E. A., Bártkai, S., Pacher, P., György, H. (2009) CB<sub>2</sub> cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. *PLoS ONE* **4**, e6409.
73. Oka, S., Yanagimoto, S., Ikeda, S., Gokoh, M., Kishimoto, S., Waku, K., Ishima, Y., Sugiura, T. (2005) Evidence for the involvement of the cannabinoid CB<sub>2</sub> receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. *J. Biol. Chem.* **280**, 18488–18497.
74. Tschop, J., Kasten, K. R., Nogueiras, R., Goetzman, H. S., Cave, C. M., England, L. G., Dattilo, J., Lentsch, A. B., Tschop, M. H., Caldwell, C. C. (2009) The cannabinoid receptor 2 is critical for the host response to sepsis. *J. Immunol.* **183**, 499–505.
75. Kraft, B., Wintersberger, W., Kress, H. G. (2004) Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP 55,940, but not by anandamide. *Life Sci.* **75**, 969–977.
76. Kraft, B., Kress, H. G. (2005) Indirect CB<sub>2</sub> receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids. *J. Pharmacol. Exp. Ther.* **315**, 641–647.
77. McHugh, D., Tanner, C., Mechoulam, R., Pertwee, R. G., Ross, R. A. (2008) Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB<sub>1</sub> and CB<sub>2</sub>. *Mol. Pharmacol.* **73**, 441–450.
78. Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L. H., Ma, Y. H., Weinander, R., Jakobsson, P. J., Marnett, L. J. (2002) Metabolism of the endocannabinoids, 2-arachidonoylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. *J. Biol. Chem.* **277**, 44877–44885.
79. Ueda, N., Yamamoto, K., Yamamoto, S., Tokunaga, T., Shirakawa, E., Shinkai, H., Ogawa, M., Sato, T., Kudo, I., Inoue, K. (1995) Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. *Biochim. Biophys. Acta* **1254**, 127–134.
80. Moody, J. S., Kozak, K. R., Ji, C., Marnett, L. J. (2001) Selective oxygenation of the endocannabinoid 2-arachidonoylglycerol by leukocyte-type 12-lipoxygenase. *Biochemistry* **40**, 861–866.
81. Kozak, K. R., Gupta, R. A., Moody, J. S., Ji, C., Boeglin, W. E., DuBois, R. N., Brash, A. R., Marnett, L. J. (2002) 15-Lipoxygenase metabolism of 2-arachidonoylglycerol. Generation of a peroxisome proliferator-activated receptor  $\alpha$  agonist. *J. Biol. Chem.* **277**, 23278–23286.
82. Leslie, C. C. (2004) Regulation of arachidonic acid availability for eicosanoid production. *Biochem. Cell Biol.* **82**, 1–17.
83. Nagaoka, I., Hirota, S., Yomogida, S., Ohwada, A., Hirata, M. (2000) Synergistic actions of antibacterial neutrophil defensins and cathelicidins. *Inflamm. Res.* **49**, 73–79.
84. Palmantier, R., Rocheleau, H., Laviolette, M., Mancini, J., Borgeat, P. (1998) Characteristics of leukotriene biosynthesis by human granulocytes in presence of plasma. *Biochim. Biophys. Acta* **1389**, 187–196.
85. Ferland, C., Guilbert, M., Davoine, F., Flamand, N., Chakir, J., Laviolette, M. (2001) Eotaxin promotes eosinophil transmigration via the activation of the plasminogen-plasmin system. *J. Leukoc. Biol.* **69**, 772–778.
86. Steinhilber, D., Radmark, O., Samuelsson, B. (1993) A heat stable serum factor upregulates 5-lipoxygenase activity in HL-60 cells, modulation by TNF  $\alpha$  or GM-CSF. *Biochem. Biophys. Res. Commun.* **193**, 1083–1090.
87. Prohászka, Z., Nemet, K., Csermely, P., Hudecz, F., Mezo, G., Fust, G. (1997) Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV-1. *Mol. Immunol.* **34**, 809–816.

## KEY WORDS:

leukotriene · cannabinoid receptor · endocannabinoid · eicosanoid · GPR55 · 5-lipoxygenase